Your browser doesn't support javascript.
SARS-CoV-2-directed antibodies persist for more than six months in a cohort with mild to moderate COVID-19.
Glück, Vivian; Grobecker, Sonja; Tydykov, Leonid; Salzberger, Bernd; Glück, Thomas; Weidlich, Tanja; Bertok, Manuela; Gottwald, Christine; Wenzel, Jürgen J; Gessner, André; Schmidt, Barbara; Peterhoff, David.
  • Glück V; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.
  • Grobecker S; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.
  • Tydykov L; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.
  • Salzberger B; Department for Infection Control and Infectious Diseases, University Hospital Regensburg, Regensburg, Germany.
  • Glück T; Kliniken Südostbayern, Traunstein, Germany.
  • Weidlich T; Kliniken Südostbayern, Traunstein, Germany.
  • Bertok M; Kliniken Südostbayern, Traunstein, Germany.
  • Gottwald C; Kliniken Südostbayern, Traunstein, Germany.
  • Wenzel JJ; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.
  • Gessner A; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.
  • Schmidt B; Institute for Medical Microbiology and Hygiene, University of Regensburg, Regensburg, Germany.
  • Peterhoff D; Institute of Clinical Microbiology and Hygiene, University Hospital Regensburg, Regensburg, Germany.
Infection ; 49(4): 739-746, 2021 Aug.
Article in English | MEDLINE | ID: covidwho-1125324
ABSTRACT

OBJECTIVE:

To follow serological immune responses of front-line healthcare workers after PCR-confirmed COVID-19 for a mean of 30 weeks, describe the time-course of SARS-CoV-2 spike protein-specific IgG, IgA and IgM levels and to identify associations of the immune response with symptoms, demographic parameters and severity of disease.

METHODS:

Anti-SARS-CoV-2 S protein-specific IgG, IgA and IgM antibodies were measured at three time points during the 30-week follow-up. COVID-19-specific symptoms were assessed with standardized questionnaires.

RESULTS:

95% of the participants mounted an IgG response with only modest decline after week 12. IgG-type antibodies were still detectable in almost 90% of the subjects at 30 weeks. IgA and IgM responses were less robust and antibody titers decreased more rapidly. At 30 weeks, only 25% still had detectable IgA-type and none had IgM-type antibodies. Higher age and higher disease severity were independently associated with higher IgG antibody levels, albeit with wide variations.

CONCLUSION:

Serological immune responses after COVID-19 show considerable inter-individual variability, but show an association with increasing age and higher severity of disease. IgG-type anti-SARS-CoV-2 antibodies remain positive in 90% of the individuals 30 weeks after onset of symptoms.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Adolescent / Adult / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Infection Year: 2021 Document Type: Article Affiliation country: S15010-021-01598-6

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Antibodies, Viral Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Adolescent / Adult / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Infection Year: 2021 Document Type: Article Affiliation country: S15010-021-01598-6